NasdaqHealth CarePharmaceutical PreparationsSOUTH SAN FRANCISCO, CA

Pliant Therapeutics, Inc. PLRX

Ask your AI

Estimated market cap $43.21M61.99M shares, shares as of Nov 9, 2026CIK 1746473

Insider trades, 12 mo

0 buys · 4 sells

$163.6K sold, open market

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

33.7% of shares · 13 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q3 2026

What changed in Pliant Therapeutics, Inc.'s latest quarterly report, compared with the one before.

Filed Nov 12, 2026 · Quarter ended Sep 30, 2026

Compared with the 10-Q for the quarter ended Jun 30, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in Pliant Therapeutics, Inc.'s latest quarterly report, compared with the one before.

Loading…

Insider trades

4 in 12 mo

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No open-market insider trades reported since Jan 20, 2026. Insiders have two business days to file.

Recent insider trades

Minnie Kuo Chief Operating Officer	Jan 20 Form 4 ↗	Sale 10b5-1 plan	−$8,854 6,917 sh @ $1.28	-56.9%
Lily Cheung Chief Human Resource Officer	Jan 20 Form 4 ↗	Sale 10b5-1 plan	−$9,644 7,534 sh @ $1.28	-56.9%
Bernard Coulie President and CEO, Director	Jan 20 Form 4 ↗	Sale 10b5-1 plan	−$114.4K 89,375 sh @ $1.28	-56.9%
Keith Lamont Cummings Chief Financial Officer	Jan 20 Form 4 ↗	Sale 10b5-1 plan	−$30.7K 24,002 sh @ $1.28	-56.9%
Mike Ouimette General Counsel & Corp. Sec'y	Jan 22, 2025 Form 4 ↗	Sale 10b5-1 plan	−$112.4K 10,230 sh @ $10.99	-118.0%

All PLRX insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

20.87M shares

48 funds report PLRX. Values checked against market prices.

Funds own 78% of shares (Q2 2026)

86 funds hold the stock.

Q3 2026: 34% · 5,560 of ~8,900 funds reported so far

Q2 202584%
Q3 202586%
Q4 202577%
Q1 202681%
Q2 202678%
Q3 2026 (so far)34%

Q3 2026. 3 new, 13 added to, 16 trimmed, 42 exited since Q2 2026.

Top 13F holders
#
1	Acadian Asset Management LLC 13F ↗	2.42M	$2.6M	unchanged
2	Vanguard Capital Management LLC 13F ↗	2.41M	$2.6M	-1.3%
3	Renaissance Technologies LLC 13F ↗	2.05M	$2.2M	+0.2%
4	Monaco Asset Management SAM 13F ↗	2.01M	$2.2M	+3.5%
5	Prosight Management, LP 13F ↗	1.60M	$1.7M	+17.1%
6	BML Capital Management, LLC 13F ↗	1.55M	$1.7M	unchanged
7	Peapod Lane Capital LLC 13F ↗	1.21M	$1.3M	-7.2%
8	BlackRock, Inc. 13F ↗	1.15M	$1.2M	+0.2%
9	Marshall Wace, LLP 13F ↗	835,124	$901.9K	unchanged
10	Geode Capital Management, LLC 13F ↗	706,938	$763.9K	+22.2%

One of these funds reports its values in thousands of dollars; its figures are shown in dollars.

Download CSV Every fund that holds PLRX, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What Pliant Therapeutics, Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What Pliant Therapeutics, Inc. and its lobbying firms report each quarter.

Loading…

H-1B labor applications at Pliant Therapeutics, Inc.

3 certified in 12 mo

Labor condition applications decided by the Department of Labor, matched to Pliant Therapeutics, Inc. by employer name. An application is not a hire.

Median yearly wage offered, full-time certified applications, Jul 2025 to Jun 2026: —

H-1B labor applications decided at Pliant Therapeutics, Inc. by quarter
Quarter	Certified	All decided	Workers asked for
2024 Q3	0	0	0
2024 Q4	0	0	0
2025 Q1	2	2	2
2025 Q2	0	0	0
2025 Q3	0	0	0
2025 Q4	0	0	0
2026 Q1	0	0	0
2026 Q2	3	3	3

Most common job titles at Pliant Therapeutics, Inc.

Data Science Lead	1	—
Modeling & Simulation Scientist	1	—
Principal, Computational Biophysics	1	—

All PLRX applications

We match the employer's name to a public company automatically, including a reviewed list of subsidiaries. A subsidiary can be missed and a similar name can be matched wrongly. The files carry no worker names.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q2 2020	37	—	27.26M	$877.4M
Q3 2020	55	+18	28.20M	$635.7M
Q4 2020	61	+6	28.53M	$648.3M
Q1 2021	76	+15	30.72M	$1.2B
Q2 2021	81	+5	30.69M	$893.6M
Q3 2021	77	-4	30.38M	$512.8M
Q4 2021	88	+11	30.88M	$416.9M
Q1 2022	92	+4	31.95M	$224.5M
Q2 2022	88	-4	30.47M	$244.1M
Q3 2022	110	+22	45.68M	$954.4M
Q4 2022	125	+15	45.20M	$873.8M
Q1 2023	143	+18	62.25M	$1.7B
Q2 2023	144	+1	58.53M	$1.1B
Q3 2023	136	-8	60.16M	$1.0B
Q4 2023	134	-2	63.55M	$1.2B
Q1 2024	135	+1	66.21M	$986.5M
Q2 2024	144	+9	64.32M	$691.5M
Q3 2024	151	+7	63.69M	$727.6M
Q4 2024	160	+9	64.75M	$852.6M
Q1 2025	140	-20	57.91M	$78.5M
Q2 2025	114	-26	51.54M	$59.8M
Q3 2025	99	-15	52.67M	$77.9M
Q4 2025	98	-1	47.06M	$58.0M
Q1 2026	91	-7	50.03M	$62.9M
Q2 2026	86	-5	48.10M	$54.8M
Q3 2026	48	-38	20.87M	$22.5M

Each point is a quarter-end, from Q2 2020 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (729139105). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q2 2020) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

About the company

The basics from the company’s SEC registration.

Legal name: PLIANT THERAPEUTICS, INC.
Address: 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA 94080
Phone: 650-481-6770
Fiscal year ends: Dec 31
Filer category: Non-accelerated filer, smaller reporting company
Incorporated in: DE
Listed as: PLRX (Nasdaq)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$0.697−$0.04 (−5.81%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $0.697 · High $0.9724Nov 13, 2026

Aug 13, 2026Low $0.697 · High $1.19Nov 13, 2026

Nov 13, 2025Low $0.697 · High $1.72Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.